List view / Grid view
12 May 2017 | By Niamh Marriott, Junior Editor
From diagnosis of HIV to successful viral suppression: this new ECDC report summarises key findings concerning and the Continuum of HIV Care in Europe...
4 May 2017 | By Niamh Marriott, Junior Editor
Abivax’s lead therapeutic candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients...
20 March 2017 | By Niamh Marriott, Junior Editor
Research published by BioMed Central’s open access journal AIDS Research and Therapy has investigated the use of lubricants...
15 March 2017 | By Mike Elliott, Vice President, Medical Affairs, Gilead Sciences
We caught up with Gilead’s Mike Elliott to find out the latest in HIV medication and whether a cure is finally within our reach…
1 December 2016 | By Niamh Louise Marriott, Digital Editor
Embarrassing Bodies' Dr Christian Jessen talks debunking the stigma surround this pandemic disease and explains why it's OK if we don't find a cure...
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
24 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood...
16 August 2016 | By ViiV Healthcare
ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…
19 July 2016 | By Victoria White, Digital Content Producer
Triumeq demonstrated superior efficacy compared with ATV/r plus TDF/FTC in 495 treatment-naïve women living with HIV...
23 June 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation for Gilead’s once-daily single tablet regimen Odefsey for the treatment of HIV-1 infection in certain patients...
Researchers are developing a new kind of treatment, an antibody-based drug called 3BNC117, that may provide a better strategy for long-term control of HIV...
28 April 2016 | By Jon Pender, VP Government Affairs, GSK
Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world...
25 April 2016 | By Victoria White, Digital Content Producer
Descovy is the first new HIV backbone approved in Europe in more than a decade and represents an important advance in addressing the needs of patients...
13 April 2016 | By Victoria White, Digital Content Producer
A study has shown that the 'prime boost' approach is compatible with co-administration of vectors encoding for HIV and HCV antigens...
7 April 2016 | By Victoria White, Digital Content Producer
Enrolment has started for two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection, VRC01...
